Arabidopsis thalianacyclin-dependent kinase
|
Recombinant scFv antigen produced in Nicotinia tabacum with no plant glycosylation |
Biologically active |
Immunomodulation against plant pathogens |
[74] |
Chimeric JEV E protein |
Recombinant Escherichia coli expressed fusion of 27-amino acid JEV peptide with Mycobacterium tuberculosis hsp70 antigen |
Chimeric protein elicited stronger immune response in mice than the single JEV antigen |
Vaccine against Japanese encephalitis virus |
[75] |
Clavanin MO |
Amino acid substitution |
Improved antibacterial activity |
Pseudomonas aeruginosa (immunomodulatory) |
[76] |
Cm-p5 |
Peptide fragmentation, de novo sequence determination, amino acid substitution |
Improved antibacterial activity |
Candida albicans, Cryptococcus neoformans, Trichophyton rubrum
|
[77] |
D5 and D6 decamers |
Systematic Arg and Trp substitution |
Improved antibacterial activity |
Gram-positive and Gram-negative bacteria |
[78] |
Escherichia coliheat-labile toxin
|
Recombinant antigen produced in Zea mays with no plant glycosylation. Retention in endoplasmic reticulum |
Biologically active |
Vaccine against pathogenic E. coli
|
[79] |
Hepatitis B surface antigen |
Recombinant antigen produced in N. tabacum with no plant glycosylation. Retention in endoplasmic reticulum |
Biologically active |
Vaccine against Hepatitis B virus |
[80] |
Human carcinoembryonic antigen |
Recombinant antigen produced transiently in N. tabacum
|
Biologically active |
Activity against colon and breast cancer |
[81] |
Japanese cedar pollen allergens |
Recombinant antigen produced in Oryza sativa with no plant glycosylation. Retention in endoplasmic reticulum |
Biologically active |
Vaccine against pollen allergy |
[82] |
Lytic base unit (LBU) |
eCAPs with 12–48 residues. Optimized amphipathic helices with only Arg and Trp residues |
Maximum antibacterial selectivity at 24 residues; increased activity at 12 residues in length |
P. aeruginosa and Staphylococcus aureus
|
[83] |
P307SQ-8C
|
C-terminal amino acid substitution |
High in vitro activity against Gram-negative bacteria biofilms. Synergistic activity with polymyxin B. Did not lyse human red blood cells or B cells |
Acinetobacter baumannii |
[36] |
Peptide derived from human lysosomal cathepsin G (cat G) |
Substitution of residues 117–136 |
Enhancement of activity against Gram-positive and Gram-negative bacteria |
S. aureus, P. aeruginosa
|
[84] |
Synthetic cxc cfcfc peptides |
Dengue fever virus and Japanese encephalitis virus synthetic peptides with motifs to fit human leukocyte antigen (HLA) |
Enhanced cellular immune response in the lymph nodes |
Vaccine against Dengue virus for populations in developing countries |
[58] |
TiBP1 |
Chimeric peptides with solid-binding kinetics to titanium substrate |
Enhanced activity |
Activity against bacteria commonly found in oral and orthopedic implants, such as Streptococcus mutans, Staphylococcus epidermidis, and E. coli
|
[85] |
WLBU2 and WR12 |
Idealized amphipathic helices with three and two amino acid substitution, respectively |
WLBU2 eradicated lethal P. aeruginosa septicemia in mice |
142 isolates of ESKAPE pathogens |
[86] |